HealthyNCT06605300
The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling
A study testing Intranasal Oxytocin (IN-OXT) and Intranasal Vasopressin (AVP) in people with Healthy, run by University of Electronic Science and Technology of China at 2 sites in China.
Trial summary
The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Intranasal Oxytocin (IN-OXT) and Intranasal Vasopressin (AVP)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 2 sitesChina
- Study dates
- 2 Oct 2024to 12 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy subjects without past or current psychiatric or neurological disorders.
Who cannot join
- History of head injury.
- Pregnant,menstruating,taking oral contraceptives.
- Medical or psychiatric illness.
Trial locations and contacts
2 sites in 1 country.
China2 sites
University of Electronic Science and Technology of China
Chengdu, Chengdu, 611731
University of Electronic Science and Technology of China (UESTC)
Chengdu, Sichuan, 611731
About this study
Official title: The Modulatory Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling
The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.
Read the detailed description
A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.
- Conditions
- Healthy
- Being tested
- Intranasal Oxytocin (IN-OXT), Intranasal Vasopressin (AVP), Intranasal Placebo
- Keywords
- oxytocin, vasopressin, delta-beta coupling
- Medical subject headings
- Diabetes Insipidus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intranasal Oxytocin (IN-OXT)Drug
Subject assigned to receive intranasal administration of oxytocin (24 IU).
Intranasal Vasopressin (AVP)Drug
Subjects assigned to receive intranasal administration of vasopressin (20 IU).
Intranasal PlaceboDrug
Subjects assigned to receive intranasal administration of placebo.
| Study group | Role | What they receive |
|---|---|---|
| oxytocin | Experimental | A single dose of 24 international units (IU) of oxytocin will be administered with 3 puffs of treatment to each nostril. Receives: Drug: Intranasal Oxytocin (IN-OXT) |
| vasopressin | Experimental | A single dose of 20 international units (IU) of vasopressin will be administered with 3 puffs of treatment to each nostril. Receives: Drug: Intranasal Vasopressin (AVP) |
| placebo | Placebo comparator | A single dose of placebo will be administered with 3 puffs of treatment to each nostril. Receives: Drug: Intranasal Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Resting-state EEG
Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index.
Measured: 35-50 minutes after treatment administration.
Behavioral indices in the tasks
Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious).
Measured: 50-90 minutes after treatment administration.
Task-based EEG
EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses.
Measured: 50-90 minutes after treatment administration.
Secondary outcomes (1)
SCR in anxiety induction
Skin Conductance Response (SCR) data are recorded in the anxiety induction task under safe and anxious conditions.
Measured: 70-90 minutes after treatment administration.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2024
- Study start2 Oct 2024
- Primary completion28 Jul 2025
- Study completion12 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Electronic Science and Technology of China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shuxia Yao, University of Electronic Science and Technology of China
- Investigators
- Shuxia Yao, Dr, Principal investigator, University of Electronic Science and Technology of China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06605300
- Sponsor's protocol ID
- UESTC-neuSCAN-96
- Status last verified
- Sep 2025
- First submitted
- 18 Sep 2024
- Last updated
- 3 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Modulatory Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling
- ClinicalTrials.gov ID
- NCT06605300
- Acronym / sponsor ID
- UESTC-neuSCAN-96
- Conditions
- Healthy
- Keywords
- oxytocin, vasopressin, delta-beta coupling
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- University of Electronic Science and Technology of ChinaUniversity, hospital or other
- Study start
- 2 Oct 2024 (actual)
- Primary completion
- 28 Jul 2025 (actual)
- Study completion
- 12 Aug 2025 (actual)
- First posted
- 20 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main aim of the study is to investigate whether intranasal oxytocin and vasopressin have effects on delta-beta cross-frequency coupling under resting-state and task conditions.
Detailed description
A double-blinded, placebo-controlled, between-subject design is employed in this study. In a randomized order, a total of 120 healthy males and females are instructed to self-administer intranasal spray of oxytocin, vasopressin, or placebo. (1) 15-minute resting-state EEG data are collected 35 minutes after treatment. (2) Participants complete tasks including Stroop, GO/NOGO, and anxiety induction with behavioral (response time, accuracy, or rating) and EEG data being collected. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), and Adult ADHD Self-Report Scale (ASRS-v1.1). Participants are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before resting state and after the tasks. Three blood samples (5 ml) are collected into 6 ml ETDA tubes when participants just arrive, before resting state recording and after all of the tasks.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| oxytocin | Experimental | Drug: Intranasal Oxytocin (IN-OXT)A single dose of 24 international units (IU) of oxytocin will be administered with 3 puffs of treatment to each nostril. |
| vasopressin | Experimental | Drug: Intranasal Vasopressin (AVP)A single dose of 20 international units (IU) of vasopressin will be administered with 3 puffs of treatment to each nostril. |
| placebo | Placebo comparator | Drug: Intranasal PlaceboA single dose of placebo will be administered with 3 puffs of treatment to each nostril. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Healthy subjects without past or current psychiatric or neurological disorders.
Key exclusion criteria (3 listed)
- History of head injury.
- Pregnant,menstruating,taking oral contraceptives.
- Medical or psychiatric illness.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intranasal Oxytocin (IN-OXT)Subject assigned to receive intranasal administration of oxytocin (24 IU). | Drug | oxytocin |
| Intranasal Vasopressin (AVP)Subjects assigned to receive intranasal administration of vasopressin (20 IU). | Drug | vasopressin |
| Intranasal PlaceboSubjects assigned to receive intranasal administration of placebo. | Drug | placebo |
Primary outcome
Resting-state EEG
Time frame: 35-50 minutes after treatment administration.
Participants are asked to sit comfortably and look at a white cross fixation against a black background on the computer monitor for 15 minutes with delta-beta cross-frequency coupling as a main index.
Behavioral indices in the tasks
Time frame: 50-90 minutes after treatment administration.
Reaction time and accuracy are recorded in the emotional Stroop and Go/Nogo tasks. For the anxiety induction task, participants are instructed to rate their anxiety levels using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very anxious).
Task-based EEG
Time frame: 50-90 minutes after treatment administration.
EEG data are recorded in the emotional Stroop, Go/Nogo, and anxiety induction tasks. Delta-beta cross-frequency coupling will be calculated to do statistical analyses.
1 secondary outcome
SCR in anxiety induction
Time frame: 70-90 minutes after treatment administration.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shuxia Yao, Dr principal investigator
University of Electronic Science and Technology of China
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intranasal Oxytocin (IN-OXT) and Intranasal Vasopressin (AVP) in people with Healthy, run by University of Electronic Science and Technology of China at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Resting-state EEG (time frame: 35-50 minutes after treatment administration.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2025.